Why the primary defence against biosimilars is to develop better molecules that can be launched quickly.
David E. Szymkowski
Advertisement
David E. Szymkowski is Senior Director of Biotherapeutics at Xencor.
Articles by David E. Szymkowski
Advertisement
Latest Updated Articles
- True Biosimilars Do Not Offer A Compelling Business Case
Published: August 1st 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
AAPS PharmSci 360: Enhancing Bioanalysis with AI and Other Technologies
4
2025 AAPS PharmSci 360 to Highlight Next-Gen AI for Drug Development
5
